Markets
Buffett
Still Oracle-ing.

The ‘Buffett Indicator’ is going nuts

What is it telling us?

Once upon a time, investors believed that the value of the US stock market was tethered in some fundamental way to the overall productive capacity of the US economy, and the publicly traded companies whose profits depended on American growth.

One of those investors was — and at age 93, still is — Warren Buffett, Chairman and CEO of insurance, investment, and industrial conglomerate Berkshire Hathaway.

That’s just his day job, however. Buffett has long played an unofficial role as American capitalism’s affable, avuncular avatar, with the press and the public seeking out his folksy common sense both when the markets are gripped by speculative fever and when there’s an all-out crisis.

Buffett’s steadying influence flows, in a sense, from his association with value investing, the school of thought we alluded to before, that focuses on the prospect of a company’s earning power and prospective dividends, and ultimately the US economy, as the basis of investment decisions.

Typically, such value investors tend to be somewhat contrarian by nature. In frothy markets, they typically warn investors that that stock prices may be overvalued, and outpacing the ability of companies to produce profits and return money to shareholders. Conversely, when the markets tumble, they tend to see bargains, arguing the investors are too pessimistic about the stability of the US economy and how much money companies stand to make in the future. As Buffett said, “Be fearful when others are greedy, and greedy when others are fearful.”

One of the tools the Oracle of Omaha famously said he looks to in order to tell where we are in such a cycle is the ratio of stock market capitalization — that the total value on paper of the stocks that are publicly traded — as a share of gross domestic product, the most comprehensive gauge of the economy. It’s become known as the “Buffett Indicator.” Here’s a version of it.

Buffett laid out his thinking about this stat in a speech, that was published in Fortune magazine back in late 2001, as the market deflated from the tech stock boom.

The ratio has certain limitations in telling you what you need to know. Still, it is probably the best single measure of where valuations stand at any given moment. And as you can see, nearly two years ago the ratio rose to an unprecedented level. That should have been a very strong warning signal.

Buffett’s well-known avoidance of the tech stock boom-and-bust of the 1990s, was perhaps one of the best calls in an investing career replete with them.

Today — thanks to the technological promise of AI, as well as the hype cycle surrounding it — we’re in another tech boom. And again, at least according to the Buffett Indicator, stocks are pretty clearly overvalued.

That’s not a reason to sell, of course. Globalization has deepened profit-making opportunities for the largest companies so the US economy may no longer be the best denominator. Buffett popularized this metric before China was even a member of the World Trade Organization.

And the market can stay overvalued for a long time, and delivering giant returns to investors as it does. Still, amid all the AI-related excitement, this common sense statistic seems worth keeping an eye on.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.